Track market-moving stories before they get noisy

Posted by Defense World Staff on Jul 26th, 2026

Dimensional Fund Advisors LP raised its stake in Olin Corporation (NYSE:OLN – Free Report) by 22.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,627,997 shares of the specialty chemicals company’s stock after buying an additional 1,031,498 shares during the quarter. Dimensional Fund Advisors LP owned about 4.94% of Olin worth $167,311,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Royal Bank of Canada lifted its stake in Olin by 20.2% during the first quarter. Royal Bank of Canada now owns 85,198 shares of the specialty chemicals company’s stock worth $2,066,000 after purchasing an additional 14,344 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Olin in the first quarter valued at $32,000. Jones Financial Companies Lllp grew its stake in shares of Olin by 467.9% in the first quarter. Jones Financial Companies Lllp now owns 13,805 shares of the specialty chemicals company’s stock valued at $335,000 after buying an additional 11,374 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Olin by 57.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 588,602 shares of the specialty chemicals company’s stock valued at $14,268,000 after buying an additional 215,235 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Olin by 6.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 317,472 shares of the specialty chemicals company’s stock valued at $7,696,000 after buying an additional 20,047 shares during the period. 88.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In OLN has been the topic of several research reports. BMO Capital Markets reduced their price target on shares of Olin from $30.00 to $25.00 and set a “market perform” rating on the stock in a research report on Monday, July 6th. The Goldman Sachs Group dropped their price objective on shares of Olin from $31.00 to $24.00 and set a “neutral” rating for the company in a report on Thursday, July 16th. JPMorgan Chase & Co. cut their target price on shares of Olin from $26.00 to $25.00 and set a “neutral” rating on the stock in a research note on Thursday, June 18th. Zacks Research upgraded shares of Olin from a “strong sell” rating to a “hold” rating in a report on Monday, April 13th. Finally, Citigroup cut shares of Olin from a “neutral” rating to an “underperform” rating in a research report on Tuesday, June 30th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, nine have assigned a Hold rating and four have given a Sell rating to the stock. According to data from MarketBeat, Olin has a consensus rating of “Hold” and a consensus target price of $26.46.

View Our Latest Research Report on OLN

Olin Price Performance Shares of OLN opened at $23.21 on Friday. The firm has a market capitalization of $2.64 billion, a price-to-earnings ratio of -20.73 and a beta of 1.21. The firm’s fifty day simple moving average is $23.23 and its 200-day simple moving average is $24.79. Olin Corporation has a twelve month low of $18.08 and a twelve month high of $30.46. The company has a current ratio of 1.36, a quick ratio of 0.82 and a debt-to-equity ratio of 1.73.

Olin Dividend Announcement The firm also recently announced a quarterly dividend, which was paid on Friday, June 12th. Investors of record on Thursday, May 14th were issued a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 3.4%. The ex-dividend date of this dividend was Thursday, May 14th. Olin’s dividend payout ratio is -71.43%.

Olin Profile (Free Report)

Olin Corporation is a diversified manufacturer specializing in chemical products and ammunition. The company’s core business activities encompass the production and distribution of chlor-alkali products, epoxy resins and derivatives, and small-caliber ammunition under the Winchester brand. Olin’s chemical operations supply chlorine, caustic soda and related co-products to a wide range of end markets, including water treatment, pulp and paper, pharmaceuticals and general industrial applications.

In its Chlor Alkali Products & Vinyls segment, Olin operates multiple manufacturing facilities that produce chlorine and sodium hydroxide, along with vinyl chloride monomer and polyvinyl chloride (PVC) compounds.

Further Reading Five stocks we like better than Olin Telecom Earnings Reveal a Sector That Finally Looks Healthier Defense Earnings Show Readiness Now and Modernization Ahead Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off MarketBeat Week in Review – 07/20- 07/24 Want to see what other hedge funds are holding OLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Olin Corporation (NYSE:OLN – Free Report).

Receive News & Ratings for Olin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olin and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEDimensional Fund Advisors LP Buys 61,404 Shares of Broadridge Financial Solutions, Inc. $BR

NEXT HEADLINE »Voya Financial, Inc. $VOYA Shares Purchased by Dimensional Fund Advisors LP

On July 22, 2026, Olin Corp (OLN) shares rose 4.7% today, reaching a current price of $24.24. The stock has shown strong momentum recently, with a 10.9% increas

, /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Olin Corporation (NYSE: OLN) related to its merger with Huntsman Corporation. Upon closing of the proposed transaction, Olin shareholders will own approximately 54.5% of the combined company. Is it a fair deal?

Click here for more info https://monteverdelaw.com/case/olin-corporation/https://monteverdelaw.com/case/psb-holdings-inc/https://monteverdelaw.com/case/xoma-royalty-corporation/https://monteverdelaw.com/case/globalstar-inc-2/https://monteverdelaw.com/case/calisa-acquisition-corp/https://monteverdelaw.com/?post_type=case&p=12170&preview=true. It is free and there is no cost or obligation to you.

NOT ALL LAW FIRMS ARE EQUAL. Before you hire a law firm, you should talk to a lawyer and ask:

Do you file class actions and go to Court? When was the last time you recovered money for shareholders? What cases did you recover money in and how much? About Monteverde & Associates PC

Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. 

No one is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.

Contact:
Juan Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4740
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341

Attorney Advertising. (C) 2026 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.

SOURCE Monteverde & Associates PC

On June 12, 2026, Olin Corp OLN shares rose 3.8% to a current price of $25.13. This price action is situated within a 52-week range of $18.08 to $30.46, showcasing a volatile trading environment over the past year.

GF Value™ verdict: Currently priced at $25.13, OLN is estimated to be 45.1% undervalued compared to its GF Value™ of $45.81.GF Score™: With a score of 65/100, OLN is categorized as above average in terms of overall stock performance potential.Most notable signal: The stock's momentum rank stands at 9/10, indicating strong recent price performance. Is OLN Overvalued or Undervalued? Olin Corp's current share price of $25.13 presents a significant discount when compared to its GF Value™ of $45.81, suggesting that the stock is undervalued by approximately 45.1%. This margin of safety may attract value-focused investors looking for potential opportunities in the market. However, the GF Valuation label indicates that OLN could be a possible value trap, which warrants caution. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.

While the significant gap between the stock price and the GF Value™ suggests potential upside, the company's financial strength rating of 3/10 indicates that there are inherent risks associated with investing in Olin Corp. Therefore, while the undervaluation may present an opportunity, investors should be diligent and consider the underlying financial health of the company before making any investment decisions.

How Does OLN's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 199.4x 10.0x The current P/E ratio of Olin Corp at 199.4x is substantially higher than its 5-year median P/E of 10.0x, indicating that the stock is trading well above its historical valuation levels. This P/E analysis supports the GF Value™ verdict of undervaluation; however, it also raises questions about the sustainability of the current price, given the steep valuation compared to historical norms.

What Does OLN's GF Score™ Tell Us? Metric Rating GF Score™ 65 Financial Strength 3/10 Profitability 5/10 Growth 4/10 Valuation 4/10 Momentum 9/10 The GF Score™ of 65/100 indicates that Olin Corp has a sound potential for long-term returns, although it manifests weaknesses in financial strength (3/10), growth (4/10), and valuation (4/10). The strongest aspect of OLN's score is its momentum rank (9/10), suggesting that the stock has been performing well in recent market conditions. Conversely, the low financial strength score points to potential risks that investors should be aware of.

What Are Insiders Doing with OLN Stock? In the past three months, there have been no insider transactions reported for Olin Corp. This lack of activity may suggest that insiders are not currently making significant moves regarding their shares, which can sometimes indicate uncertainty about the company's prospects or a wait-and-see approach regarding future performance.

What This Means for Investors Based on the GF Value™ assessment, Olin Corp is currently undervalued. However, potential investors should proceed with caution due to the company's low financial strength and high current P/E ratio, which may reflect risks that could affect future performance.

For the complete analysis, visit the Olin Corp OLN stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is OLN's GF Score™?

OLN's GF Score™ is 65/100, indicating that the stock is above average in potential for long-term returns based on several key performance metrics.

Is OLN overvalued or undervalued?

Olin Corp is currently undervalued, with a GF Value™ of $45.81 compared to its current price of $25.13, suggesting a potential upside.

What is OLN's P/E ratio?

The current P/E ratio for Olin Corp is 199.4x, which is significantly higher than its 5-year median P/E of 10.0x, indicating it is trading above historical levels.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

OLN324 demonstrated meaningfully faster and greater improvements in anatomic outcomes in DME and numerically greater vision gains sustained through 20 weeks with fewer retreatments as compared to faricimab New anatomic data demonstrates OLN324 achieves faster, greater, and more durable reductions in wAMD pigment epithelial detachment (PED) thickness versus faricimab Ollin and Innovent Biologics advancing OLN324 into global Phase 3 studies in DME and wAMD in 2026 , /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, today announced that the company's partner Ollin reported final, 20-week study completion data from its randomized, head-to-head Phase 1b JADE clinical study comparing OLN324(Innovent R&D code IBI324) , a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody, to faricimab (Vabysmo®), in patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD). Final results released include favorable durability data for OLN324 compared to faricimab and new anatomic data showing faster, greater, and more durable control of wAMD pigment epithelial detachments (PEDs) with OLN324.

Topline data from the Week 12 primary endpoint readout, previously announced in January 2026 and presented at the Angiogenesis, Exudation, and Degeneration Symposium in February 2026, demonstrated OLN324, compared to faricimab, delivered superior anatomic outcomes in DME, including faster and greater retinal drying and more patients achieving absence of DME; equivalent retinal drying compared to faricimab in wAMD; rapid and sustained gains in vision in both DME and wAMD that were numerically better than faricimab; and had a favorable safety profile with no cases of intraocular inflammation. 

Final 20-Week Study Completion Data Highlights

The JADE trial, which enrolled 164 U.S. patients with either DME or wAMD, all patients initially received three monthly doses of OLN324 or faricimab. Thereafter, they were followed for an additional 12 weeks off treatment, during which they could be retreated based on protocol-specified criteria for disease recurrence that were the same for all groups.

At the final study visit at Week 20, 12 weeks after the last mandatory dose, DME patients treated with OLN324 continued to demonstrate greater retinal drying compared to those treated with faricimab, measured as mean change in central subfield thickness on optical coherence tomography, along with sustained vision gains that were numerically greater for OLN324 4 mg.

These improved efficacy outcomes were achieved with fewer retreatments compared to faricimab. 93% of DME patients randomized to OLN324 4 mg completed 12 weeks of follow-up without retreatment, versus 89% of patients randomized to faricimab.

In wAMD, the rapid and comparable improvements in retinal drying (mean change in OCT CST) observed from Day 1 to Week 12 with OLN324 and faricimab were sustained through Week 20. Patients treated with OLN324 experienced numerically greater vision gains than patients treated with faricimab; the BCVA improvements continued to separate between groups from Weeks 12 to 20, with a mean +2.2 letter advantage observed over faricimab for OLN324 4 mg at Week 20.

82% of OLN324 4 mg patients completed 12 weeks of follow-up without retreatment, compared with 81% of faricimab patients.

OLN324 continued to demonstrate a favorable safety profile, with zero cases of intraocular inflammation observed through the entirety of the study, compared with one case in a faricimab-treated patient. There were no cases of retinal vasculitis or occlusive retinal vasculitis with OLN324.

"These new JADE study data further strengthen the differentiated profile of OLN324, highlighting its robust anatomic efficacy and durability across both DME and wAMD. Combined with a favorable safety profile, these results underscore OLN324's potential to become a first-line treatment option for these vision-threatening diseases," said Jason Ehrlich, M.D., Ph.D., Co-founder and Chief Executive Officer of Ollin Biosciences. "We look forward to advancing OLN324 into global Phase 3 studies in both DME and wAMD later this year. Subject to regulatory communications, we expect the Phase 3 studies to recruit patients from North America, South America, Europe and Japan, and we are actively planning, in partnership with Innovent Biologics, to include China and South Korea."

"We are pleased to see that the latest 20-week data for OLN324 (IBI324) further highlight its differentiated profile and clinical potential," said Dr. Lei Qian, M.D., Ph.D., Chief R&D Officer of General Biomedicine at Innovent Biologics. "We look forward to continuing our close collaboration with Ollin and, following discussions with regulatory authorities, to accelerate the global Phase 3 clinical development of this best-in-disease therapy for retinal diseases."

New Anatomic Results on Pigment Epithelial Detachment (PED) Flattening Highlight Potential for Smaller-Format, Higher-Potency OLN324 to Improve Treatment of wAMD

In newly-available, pre-specified data, wAMD patients in the JADE trial randomized to OLN324 4 mg experienced faster and approximately 50% greater reductions in PED thickness at Week 12 compared to patients randomized to faricimab, measured as mean change in neovascular lesion complex thickness on optical coherence tomography (OCT). Through Week 20, in the off-treatment follow-up period, these improvements were more durable for patients randomized to OLN324 4 mg than faricimab.

"As a field, we've been looking for meaningful advancements that further improve anatomic outcomes in wAMD," said David Eichenbaum, M.D., FASRS, Director of Research, Retina Vitreous Associates of Florida. "These data suggest that OLN324's more potent Ang2 inhibition and smaller molecular format may translate into breaking through the efficacy ceiling experienced with current treatments and offering a clinically-relevant benefit in PED improvement – the most difficult to treat component of wAMD."

Retinal fluid (intraretinal and subretinal) and PEDs are two hallmark anatomic features of wAMD. PEDs are present in approximately 80% of wAMD patients. Persistent PEDs following anti-VEGF treatment are associated with development of subretinal fibrosis, an important cause of late vision loss in wAMD.

Full details of the final JADE study data are expected to be presented at upcoming medical and scientific conferences.

About the OLN324 JADE Study

JADE is a randomized, head-to-head Phase 1b clinical study comparing OLN324, a next-generation VEGF/Ang2 bispecific antibody, to faricimab (Vabysmo®), in patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD). More than 160 patients with wAMD or DME were enrolled at sites in the United States. All patients initially received three monthly doses of either OLN324 2 mg, OLN324 4 mg, or faricimab 6 mg. Patients were evaluated at Weeks 1, 4, 8, 12, 16, and 20 and could be retreated at Weeks 12 or 16 based on protocol-specified retreatment criteria that were the same for all groups. The primary objective was to assess safety and tolerability (through Week 12 and Week 20). Prespecified exploratory efficacy objectives included the evaluation of OLN324 vs faricimab on visual acuity and various retinal anatomic parameters.

About OLN324

Building on the clinical success of intravitreal VEGF/Ang2 inhibition, OLN324 is a next-generation VEGF/Ang2 bispecific antibody engineered with substantially higher Ang2 potency relative to faricimab, increased molar dosing relative to both faricimab and aflibercept (including Eylea HD®), and a smaller protein format. VEGF and Ang2 are central drivers of retinal vascular diseases such as diabetic macular edema (DME) and wet (neovascular) age-related macular degeneration (wAMD), with Ang2 playing a key role in vascular instability, leakage, inflammation, and fibrosis. OLN324 was discovered by and is being developed in collaboration with Innovent Biologics (HKEX: 01801; Innovent R&D code: IBI324).

About Diabetic Macular Edema (DME)

Diabetic macular edema, a vision-threatening complication of diabetic eye disease, is a leading cause of vision loss among working-age adults in the developed world. In diabetic macular edema, progressive microvasculature damage, ischemia and microvascular inflammation result in vascular leakage and retinal swelling that compromise vision.

About Wet Age-Related Macular Degeneration (wAMD)

Age-Related Macular Degeneration, a chronic and progressive retinal disease, is the leading cause of vision loss among older adults in the developed world. In wet (or neovascular) AMD, abnormal blood vessels growing beneath the retina leak and bleed, resulting in significant vision impairment.

About Ollin Biosciences

Established in 2023, Ollin BiosciencesTM is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. With a differentiated pipeline, world-class team, and strong investor syndicate, Ollin is redefining what's possible in ophthalmology. For more information, please visit us at www.ollin.bio and follow us on LinkedIn and X.

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 18 products in the market. It has 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, "Start with Integrity, Succeed through Action" Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Disclaimer: Innovent does not recommend any off-label usage.

Vabysmo® is a registered trademark of Genentech, Inc.; Eylea® and Eylea HD® are registered trademarks of Regeneron Pharmaceuticals, Inc.

Forward-looking statement

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions.

The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.

SOURCE Innovent Biologics

Olin remains a buy as Middle East conflict tightens global petrochemical supply, supporting US-centric producers and improving pricing power. OLN's Q1 likely marks the bottom, with Q2 expected to benefit from lower US natural gas prices and improved margins, especially in Chlor Alkali. Despite weak construction demand, supply disruptions and cost tailwinds should drive at least $150M free cash flow in 2026, with further upside possible.

Highlights

First quarter 2026 net loss of ($83.0) million, or ($0.73) per diluted share Quarterly adjusted EBITDA of $86.2 million , /PRNewswire/ -- Olin Corporation (NYSE: OLN) announced financial results for the first quarter ended March 31, 2026. First quarter 2026 reported net loss was ($83.0) million, or ($0.73) per diluted share, which compares to first quarter 2025 reported net income of $1.4 million, or $0.01 per diluted share. First quarter 2026 adjusted EBITDA of $86.2 million excludes depreciation and amortization expense of $117.2 million, restructuring charges of $9.1 million and legacy litigation charges of $36.1 million. First quarter 2025 adjusted EBITDA was $185.6 million. Sales in the first quarter 2026 were $1,583.0 million, compared to $1,644.2 million in the first quarter 2025.

Ken Lane, President and Chief Executive Officer, said, "During the first quarter, the Olin team delivered sequential improvement in adjusted EBITDA. Our Chlor Alkali Products and Vinyls business benefited from favorable operating cost performance driven by our Beyond250 structural cost actions and lower than expected planned maintenance turnaround expenses. Our Epoxy business returned to positive adjusted EBITDA underpinned by growth in its European business, supported by structurally improved costs at our Stade, Germany facility. Winchester's sequential improvement was driven by actions taken late last year to accelerate channel inventory destocking, as well as improving demand and pricing measures implemented to offset commodity metals and raw materials cost inflation.

"Late in the first quarter, the Iran conflict began to impact trade flows and to increase raw material and feedstock costs. As global supply shortages persist into the second quarter and potentially beyond, our advantaged North American asset base positions us to reliably serve our customers.

"Looking ahead, our Chemicals businesses are expected to deliver sequential earnings improvement driven by seasonally stronger demand and improved pricing, particularly for ethylene dichloride, caustic soda, and epoxy resins. In our Winchester business, improving commercial and military demand are expected to support sequential earnings growth. Overall, second quarter 2026 adjusted EBITDA is forecast to be in the range of $160 million to $200 million," Lane concluded.

SEGMENT REPORTING

Olin defines segment earnings as income (loss) before interest expense, interest income, other operating income (expense), non-operating pension income, other income, and income taxes.

CHLOR ALKALI PRODUCTS AND VINYLS

Chlor Alkali Products and Vinyls sales for the first quarter 2026 were $756.9 million, compared to $924.5 million in the first quarter 2025. The decrease in sales was due to lower volumes, primarily resulting from lower trading volumes associated with Blue Water Alliance, and lower pricing. The Blue Water Alliance joint venture concluded operations at the end of 2025. First quarter 2026 segment loss was ($44.5) million, compared to segment earnings of $78.3 million in the first quarter 2025. The $122.8 million decrease in segment earnings was primarily due to lower pricing and volumes, higher raw material costs, primarily natural gas and electrical power costs, and higher planned maintenance turnaround expenses, partially offset by lower operating costs. Segment results included $36.1 million in legacy litigation costs. Chlor Alkali Products and Vinyls first quarter 2026 results included depreciation and amortization expense of $93.2 million compared to $107.2 million in the first quarter 2025.

EPOXY

Epoxy sales for the first quarter 2026 were $355.6 million, compared to $331.7 million in the first quarter 2025. First quarter 2026 segment loss was ($2.9) million, compared to segment loss of ($28.4) million in the first quarter 2025. The $25.5 million increase in segment results was primarily due to lower operating costs and higher volumes. Product margins were slightly lower year over year. Epoxy first quarter 2026 results included depreciation and amortization expense of $11.9 million compared to $12.8 million in the first quarter 2025.

WINCHESTER

Winchester sales for the first quarter 2026 were $470.5 million, compared to $388.0 million in the first quarter 2025. The increase in sales was primarily due to higher military project revenue and military sales, and higher commercial ammunition sales. First quarter 2026 segment earnings were $15.2 million, compared to $22.8 million in the first quarter 2025. The $7.6 million decrease in segment earnings was primarily due to higher raw material costs, primarily commodity metal costs, and higher operating costs, partially offset by higher commercial ammunition pricing and higher military project revenue. Winchester first quarter 2026 results included depreciation and amortization expense of $8.9 million compared to $9.5 million in the first quarter 2025.

CORPORATE AND OTHER COSTS

Other corporate and unallocated costs in the first quarter of 2026 increased $13.2 million compared to the first quarter 2025 primarily due to higher incentive costs, primarily mark-to-market on stock-based compensation, and an unfavorable impact from foreign currency.

LIQUIDITY AND DIVIDENDS

The cash balance on March 31, 2026, was $192.2 million. Olin ended the first quarter 2026 with net debt of approximately $2.8 billion and a net debt to adjusted EBITDA ratio of 5.1 times. On March 31, 2026, Olin had available liquidity of approximately $1.3 billion, including unrestricted access to the undrawn portion of its revolving credit facility. Working capital increased $56.8 million in the first quarter 2026 due to normal seasonality tempered by a disciplined cash management approach.

On April 29, 2026, Olin's Board of Directors declared a dividend of $0.20 on each share of Olin common stock.  The dividend is payable on June 12, 2026, to shareholders of record at the close of business on May 14, 2026.  This will be the 398th consecutive quarterly dividend to be paid by the Company.

CONFERENCE CALL INFORMATION

Olin senior management will host a conference call to discuss first quarter 2026 financial results at 9:00 a.m. Eastern Time on Friday, May 8, 2026. Remarks will be followed by a question-and-answer session. Associated slides and the conference call webcast are accessible via Olin's website, www.olin.com, under the first quarter conference call icon. An archived replay of the webcast will also be available in the Investor Relations section of Olin's website beginning at 12:00 p.m. Eastern Time. A final transcript of the call will be posted the next business day.

COMPANY DESCRIPTION

Olin Corporation is a leading vertically integrated global manufacturer and distributor of chemical products and a leading U.S. manufacturer of ammunition. The chemical products produced include chlorine and caustic soda, vinyls, epoxies, chlorinated organics, bleach, hydrogen, and hydrochloric acid. Winchester's principal manufacturing facilities produce and distribute sporting ammunition, law enforcement ammunition, reloading components, small caliber military ammunition and components, industrial cartridges, and clay targets, along with contracted U.S. military project revenue.

Visit www.olin.com for more information on Olin Corporation.

FORWARD-LOOKING STATEMENTS

This communication includes forward-looking statements. These statements relate to analyses and other information that are based on management's beliefs, certain assumptions made by management, forecasts of future results, and current expectations, estimates and projections about the markets and economy in which we and our various segments operate. The statements contained in this communication that are not statements of historical fact may include forward-looking statements that involve a number of risks and uncertainties.

We have used the words "anticipate," "intend," "may," "expect," "believe," "should," "plan," "outlook," "project," "estimate," "forecast," "optimistic," "target," and variations of such words and similar expressions in this communication to identify such forward-looking statements. These statements are not guarantees of future performance and involve certain risks, uncertainties, and assumptions, which are difficult to predict and many of which are beyond our control. Therefore, actual outcomes and results may differ materially from those matters expressed or implied in such forward-looking statements. We undertake no obligation to update publicly any forward-looking statements, whether as a result of future events, new information or otherwise. The payment of cash dividends is subject to the discretion of our Board of Directors and will be determined in light of then-current conditions, including our earnings, our operations, our financial conditions, our capital requirements and other factors deemed relevant by our Board of Directors. In the future, our Board of Directors may change our dividend policy, including the frequency or amount of any dividend, in light of then-existing conditions.

The risks, uncertainties and assumptions involved in our forward-looking statements, many of which are discussed in more detail in our filings with the SEC, including without limitation the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2025, and our Quarterly Reports on Form 10-Q and other reports furnished or filed with the SEC, include, but are not limited to, the following:

Business, Industry and Operational Risks

sensitivity to economic, business and market conditions in the United States and overseas, including economic instability or a downturn in the sectors served by us; declines in average selling prices for our products and the supply/demand balance for our products, including the impact of excess industry capacity or an imbalance in demand for our chlor alkali products; unsuccessful execution of our operating model, which prioritizes Electrochemical Unit (ECU) margins over sales volumes; failure to control costs and inflation impacts or failure to achieve targeted cost reductions; availability of and/or higher-than-expected costs of raw material, energy, transportation, and/or logistics; our reliance on a limited number of suppliers for specified feedstock and services and our reliance on third-party transportation; the occurrence of unexpected manufacturing interruptions and outages, including those occurring as a result of labor disruptions and production hazards; exposure to physical risks associated with climate-related events or increased severity and frequency of severe weather events; the failure or an interruption, including cyber-attacks, of our information technology systems; risks associated with our international sales and operations, including economic, political or regulatory changes; weak industry conditions affecting our ability to comply with the financial maintenance covenants in our debt agreements; our indebtedness and debt service obligations; failure to identify, attract, develop, retain and motivate qualified employees throughout the organization and ability to manage executive officer and other key senior management transitions; adverse conditions in the credit and capital markets, limiting or preventing our ability to borrow or raise capital; our inability to complete future acquisitions or joint venture transactions or successfully integrate them into our business; the effects of any declines in global equity markets on asset values and any declines in interest rates or other significant assumptions used to value the liabilities in, and funding of, our pension plans; our long-range plan assumptions not being realized, causing a non-cash impairment charge of long-lived assets; Legal, Environmental and Regulatory Risks

changes in, or failure to comply with, legislation or government regulations or policies, including changes regarding our ability to manufacture or use certain products and changes within the international markets in which we operate; new regulations or public policy changes regarding the transportation of hazardous chemicals and the security of chemical manufacturing facilities; unexpected outcomes from legal or regulatory claims and proceedings; costs and other expenditures in excess of those projected for environmental investigation and remediation or other legal proceedings; and various risks associated with our Lake City U.S. Army Ammunition Plant contract and performance under other governmental contracts. All of our forward-looking statements should be considered in light of these factors. In addition, other risks and uncertainties not presently known to us or that we consider immaterial could affect the accuracy of our forward-looking statements.

2026-06

Olin Corporation

Consolidated Statements of Operations (a)

Three Months Ended
March 31,

($ in millions, except per share amounts)

2026

2025

Sales

$   1,583.0

$   1,644.2

Operating Expenses:

Cost of Goods Sold

1,507.2

1,495.5

Selling and Administrative

145.0

101.0

Restructuring Charges

9.1

4.0

Operating (Loss) Income

(78.3)

43.7

Losses of Non-consolidated Affiliates

(1.4)

—

Interest Expense

(43.2)

(48.5)

Interest Income

1.1

1.2

Non-operating Pension Income

3.5

5.7

Income (Loss) before Taxes

(118.3)

2.1

Income Tax (Benefit) Provision

(35.3)

0.9

Net (Loss) Income

(83.0)

1.2

Net Loss Attributable to Noncontrolling Interests

—

(0.2)

Net (Loss) Income Attributable to Olin Corporation

$      (83.0)

$          1.4

Net (Loss) Income Attributable to Olin Corporation per Common Share:

Basic

$      (0.73)

$        0.01

Diluted

$      (0.73)

$        0.01

Dividends per Common Share

$        0.20

$        0.20

Average Common Shares Outstanding - Basic

113.8

115.3

Average Common Shares Outstanding - Diluted

113.8

116.6

(a)     Unaudited.

Olin Corporation

Segment Information (a)

Three Months Ended
March 31,

($ in millions)

2026

2025

Sales:

Chlor Alkali Products and Vinyls

$      756.9

$      924.5

Epoxy

355.6

331.7

Winchester

470.5

388.0

Total Sales

$   1,583.0

$   1,644.2

Income (Loss) before Taxes:

Chlor Alkali Products and Vinyls

$      (44.5)

$        78.3

Epoxy

(2.9)

(28.4)

Winchester

15.2

22.8

Corporate/Other:

      Environmental Expense

(5.2)

(5.0)

      Other Corporate and Unallocated Costs

(33.2)

(20.0)

    Restructuring Charges

(9.1)

(4.0)

Interest Expense

(43.2)

(48.5)

Interest Income

1.1

1.2

Non-operating Pension Income

3.5

5.7

Income (Loss) before Taxes

$    (118.3)

$          2.1

(a)     Unaudited.

Olin Corporation

Consolidated Balance Sheets (a)

March 31,

December 31,

March 31,

($ in millions, except per share data)

2026

2025

2025

Assets:

  Cash and Cash Equivalents

$            192.2

$            167.6

$            174.0

  Accounts Receivable, Net

915.4

844.5

1,107.3

  Income Taxes Receivable

58.7

66.6

15.8

  Inventories, Net

827.2

784.5

875.2

  Other Current Assets

103.2

107.9

79.0

    Total Current Assets

2,096.7

1,971.1

2,251.3

Property, Plant and Equipment (Less Accumulated Depreciation of
$5,565.6, $5,508.7 and $5,291.8)

2,129.3

2,196.9

2,266.5

  Operating Lease Assets, Net

301.7

298.6

289.0

  Deferred Income Taxes

45.4

47.2

54.5

  Other Assets

1,188.2

1,210.0

1,171.6

  Intangibles, Net

164.8

174.4

198.6

  Goodwill

1,427.7

1,427.6

1,423.5

Total Assets

$         7,353.8

$         7,325.8

$         7,655.0

Liabilities and Shareholders' Equity:

  Current Installments of Long-term Debt

$                  —

$            109.7

$              19.2

  Accounts Payable

911.4

806.1

812.0

  Income Taxes Payable

13.1

23.9

116.9

  Current Operating Lease Liabilities

60.5

59.7

62.5

  Accrued Liabilities

558.7

630.1

428.4

    Total Current Liabilities

1,543.7

1,629.5

1,439.0

  Long-term Debt

2,996.1

2,717.6

3,016.6

  Operating Lease Liabilities

254.3

252.5

231.9

  Accrued Pension Liability

198.3

200.9

207.6

  Deferred Income Taxes

280.7

317.6

417.9

  Other Liabilities

346.0

337.1

303.9

Total Liabilities

5,619.1

5,455.2

5,616.9

Commitments and Contingencies

Shareholders' Equity:

Common Stock, $1.00 Par Value Per Share; Authorized 240.0 Shares;
Issued and Outstanding 113.9, 113.6 and 115.1 Shares

113.9

113.6

115.1

Additional Paid-in Capital

4.8

—

—

Accumulated Other Comprehensive Loss

(418.4)

(414.5)

(430.6)

Retained Earnings

2,034.0

2,139.8

2,321.5

Olin Corporation's Shareholders' Equity

1,734.3

1,838.9

2,006.0

Noncontrolling Interests

0.4

31.7

32.1

Total Equity

1,734.7

1,870.6

2,038.1

Total Liabilities and Equity

$         7,353.8

$         7,325.8

$         7,655.0

(a)     Unaudited.

Olin Corporation

Consolidated Statements of Cash Flows (a)

Three Months Ended
March 31,

($ in millions)

2026

2025

Operating Activities:

Net (Loss) Income

$      (83.0)

$          1.2

Depreciation and Amortization

117.2

132.2

Losses of Non-consolidated Affiliates

1.4

—

Stock-based Compensation

4.7

4.0

Deferred Income Taxes

(34.3)

(18.2)

Qualified Pension Plan Contributions

(0.3)

(0.1)

Qualified Pension Plan Income

(3.0)

(5.0)

Changes in Assets and Liabilities:

Receivables

(73.9)

(98.2)

Income Taxes Receivable/Payable

(2.8)

(34.0)

Inventories

(44.3)

(43.9)

Other Current Assets

1.5

4.2

Accounts Payable and Accrued Liabilities

62.7

(32.5)

Other Assets

1.5

4.6

Other Noncurrent Liabilities

6.6

1.1

Other Operating Activities

(2.6)

(1.4)

Net Operating Activities

(48.6)

(86.0)

Investing Activities:

Capital Expenditures

(43.7)

(61.4)

Investments in Non-consolidated Affiliates

(0.3)

—

Other Investing Activities

1.0

(1.0)

Net Investing Activities

(43.0)

(62.4)

Financing Activities:

Long-term Debt Borrowings, Net

170.3

199.9

Common Stock Repurchased and Retired

—

(20.2)

Stock Options Exercised

2.1

1.9

Dividends Paid

(22.8)

(23.0)

Distributions to Noncontrolling Interests

(31.3)

—

Debt Issuance Costs

(2.1)

(12.0)

Net Financing Activities

116.2

146.6

Effect of Exchange Rate Changes on Cash and Cash Equivalents

—

0.2

Net Increase (Decrease) in Cash and Cash Equivalents

24.6

(1.6)

Cash and Cash Equivalents, Beginning of Year

167.6

175.6

Cash and Cash Equivalents, End of Period

$      192.2

$      174.0

(a)

Unaudited. 

Olin Corporation

Non-GAAP Financial Measures - Adjusted EBITDA (a)

Olin's definition of Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) is net income (loss) plus 
an add-back for depreciation and amortization, interest expense (income), income tax provision (benefit), other expense
(income), restructuring charges (income) and certain other non-recurring items. Adjusted EBITDA is a non-GAAP financial
measure. Management believes that this measure is meaningful to investors as a supplemental financial measure to assess the
financial performance without regard to financing methods, capital structures, taxes or historical cost basis. The use of non-
GAAP financial measures is not intended to replace any measures of performance determined in accordance with GAAP and
Adjusted EBITDA presented may not be comparable to similarly titled measures of other companies. Reconciliation of forward-
looking non-GAAP financial measures to the most directly comparable GAAP financial measures are omitted from this release
because Olin is unable to provide such reconciliations without the use of unreasonable efforts. This inability results from the
inherent difficulty in forecasting generally and quantifying certain projected amounts that are necessary for such reconciliations.
In particular, sufficient information is not available to calculate certain adjustments required for such reconciliations, including
interest expense (income), income tax provision (benefit), other expense (income) and restructuring charges (income). Because
of our inability to calculate such adjustments, forward-looking net income guidance is also omitted from this release. We expect
these adjustments to have a potentially significant impact on our future GAAP financial results.

Three Months Ended
March 31,

($ in millions)

2026

2025

Reconciliation of Net (Loss) Income to Adjusted EBITDA:

Net (Loss) Income

$         (83.0)

$            1.2

Add Back:

Interest Expense

43.2

48.5

Interest Income

(1.1)

(1.2)

Income Tax (Benefit) Provision

(35.3)

0.9

Depreciation and Amortization

117.2

132.2

EBITDA

41.0

181.6

Add Back:

Restructuring Charges

9.1

4.0

Legacy Litigation Matters

36.1

—

Adjusted EBITDA

$          86.2

$        185.6

(a) Unaudited.

Olin Corporation

Non-GAAP Financial Measures - Net Debt to Adjusted EBITDA (a)

Olin's definition of Net Debt to Adjusted EBITDA is Net Debt divided by Adjusted EBITDA. Net Debt at the end of any
reporting period is defined as the sum of our current installments of long-term debt and long-term debt, less cash and cash
equivalents. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) is net income (loss) plus an add-
back for depreciation and amortization, interest expense (income), income tax provision (benefit), other expense (income),
restructuring charges (income) and certain other non-recurring items. Net Debt to Adjusted EBITDA is a non-GAAP financial
measure. Management believes that this measure is meaningful to investors as a measure of our ability to manage our
indebtedness. The use of non-GAAP financial measures is not intended to replace any measures of indebtedness or liquidity
determined in accordance with GAAP and Net Debt or Net Debt to Adjusted EBITDA presented may not be comparable to
similarly titled measures of other companies.

March 31,

December 31,

March 31,

($ in millions)

2026

2025

2025

Current Installments of Long-term Debt

$                  —

$            109.7

$              19.2

Long-term Debt

2,996.1

2,717.6

3,016.6

Total Debt

2,996.1

2,827.3

3,035.8

Less: Cash and Cash Equivalents

(192.2)

(167.6)

(174.0)

Net Debt

$         2,803.9

$         2,659.7

$         2,861.8

Trailing Twelve Months Adjusted EBITDA (b)

$            552.4

$            651.8

$            817.4

Net Debt to Adjusted EBITDA

5.1

4.1

3.5

(a)

Unaudited.

(b)

Trailing Twelve Months Adjusted EBITDA as of March 31, 2026 is calculated as the three months ended March 31, 2026 plus
the year ended December 31, 2025 less the three months ended March 31, 2025. Trailing Twelve Months Adjusted EBITDA
as of March 31, 2025 is calculated as the three months ended March 31, 2025 plus the year ended December 31, 2024 less
the three months ended March 31, 2024.

SOURCE Olin Corporation

Olin (OLN - Free Report) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to earnings of $0.04 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +3.10%. A quarter ago, it was expected that this chlor-alkali and ammunition producer' would post a loss of $0.58 per share when it actually produced a loss of $0.58, delivering no surprise.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Olin, which belongs to the Zacks Chemical - Diversified industry, posted revenues of $1.58 billion for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 1.11%. This compares to year-ago revenues of $1.64 billion. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Olin shares have added about 38.3% since the beginning of the year versus the S&P 500's gain of 7.6%.

What's Next for Olin?While Olin has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Olin was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.01 on $1.68 billion in revenues for the coming quarter and -$0.90 on $6.63 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Chemical - Diversified is currently in the top 36% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the broader Zacks Basic Materials sector, Avino Silver (ASM - Free Report) , is yet to report results for the quarter ended March 2026. The results are expected to be released on May 13.

This company is expected to post quarterly earnings of $0.07 per share in its upcoming report, which represents no change from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Avino Silver's revenues are expected to be $35.1 million, up 86.3% from the year-ago quarter.

Key Takeaways Olin posted a narrower-than-expected Q1 loss as Winchester sales offset weaker Chemicals demand.OLN's Winchester sales jumped on military projects and stronger commercial ammunition demand.Olin expects Q2 EBITDA of $160M-$200M amid stronger demand and pricing improvements. Olin Corporation (OLN - Free Report) reported a first-quarter 2026 adjusted loss of 65 cents per share, narrower than the Zacks Consensus Estimate of a loss of 67 cents, delivering a 3% earnings surprise.

On a reported basis, the company posted a net loss of $83 million, or 73 cents, versus year-ago net income of $1.4 million, or a penny per share.

Sales were $1,583 million, down 3.7% year over year but ahead of the consensus estimate of $1,565.6 million by 1.1%.

Adjusted EBITDA came in at $86.2 million, with results reflecting weaker Chemicals conditions that were partially offset by stronger Winchester sales.

OLN's Segmental ReviewChlor Alkali Products and Vinyls sales were $756.9 million, down from $924.5 million in the year-ago quarter. The reported figure missed the consensus estimate of $799 million. Olin attributed the decline to lower volumes and pricing, with volumes pressured by reduced trading activity tied to the Blue Water Alliance joint venture, which concluded operations at the end of 2025.

Epoxy sales increased to $355.6 million from $331.7 million, supported by higher volumes. The metric beat the consensus estimate of $349 million. Segment loss was lower due to lower operating costs, even as product margins were slightly down year over year.

Winchester sales rose to $470.5 million from $388 million, driven by higher military project revenues and military sales, along with higher commercial ammunition sales. It outpaced the consensus estimate of $408 million.

OLN's FinancialsOlin ended the quarter with cash and cash equivalents of $192.2 million. Net debt was approximately $2.8 billion. Net cash used in operating activities was $48.6 million in the first quarter, compared with $86 million used in the prior-year quarter. Olin paid $22.8 million in dividends and did not repurchase common stock during the quarter.

OLN's OutlookManagement expects sequential improvement in Chemicals in the second quarter, driven by seasonally stronger demand and improved pricing, particularly for ethylene dichloride, caustic soda and epoxy resins. In Winchester, the company sees improving commercial and military demand supporting sequential earnings growth, alongside pricing measures aimed at offsetting raw material inflation.

Olin guided second-quarter 2026 adjusted EBITDA to a range of $160 million to $200 million. The company also noted that the Iran conflict began impacting trade flows late in the first quarter and lifted raw material and feedstock costs, with global supply shortages potentially persisting into the second quarter and beyond.

Olin’s Price PerformanceShares of Olin have gained 26.2% in the past year, compared with 13.1% rise of the industry.

Image Source: Zacks Investment Research

OLN’s Zacks Rank & Key PicksOLN currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the basic materials space are Idaho Strategic Resources, Inc. (IDR - Free Report) , NioCorp Developments Ltd. (NB - Free Report) and Hawkins, Inc. (HWKN - Free Report) .

Idaho is expected to report first-quarter 2026 results on May 14. The Zacks Consensus Estimate for earnings is pegged at 43 cents per share, indicating 258.33% year-over-year growth. IDR sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here. 

NioCorp is expected to report third-quarter fiscal 2026 results on May 14. The consensus estimate for NB’s loss per share is pegged at 2 cents, indicating 83.33% year-over-year growth. NB presently flaunts a Zacks Rank #1.

Hawkins is scheduled to report fiscal fourth-quarter 2026 results on May 13. The Zacks Consensus Estimate for HWKN’s first-quarter earnings per share is pegged at 77 cents. HWKN carries a Zacks Rank #2 (Buy) at present.

On May 29, 2026, Olin Corp OLN shares fell 3.3% to a current price of $25.87, reflecting a broader trend as the stock has decreased 4.8% over the past month. The price has fluctuated between a 52-week high of $30.46 and a low of $18.08.

GF Value™ verdict: Current price of $25.87 is 43.3% undervalued compared to the GF Value™ of $45.61.GF Score™ of 63/100 indicates an above-average stock performance potential.Most notable signal: Momentum rank of 9/10 suggests strong recent performance despite the current price drop. Is OLN Overvalued or Undervalued? The current price of Olin Corp OLN at $25.87 represents a significant discount to the GF Value™, which estimates the fair value at $45.61. This indicates that the stock is trading at a 43.3% margin of safety. However, the GF Valuation label of "Possible Value Trap, Think Twice" introduces caution. While this undervaluation suggests an opportunity, it also implies that the company's fundamentals might not support a recovery to its intrinsic value. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.

Investors should be aware that while the stock appears undervalued, the low financial strength score of 3/10 and a Piotroski F-Score of 4 indicate potential underlying issues that could hinder price recovery. The Altman Z-Score of 1.67 also suggests that the company may be at risk of financial distress, raising concerns about the sustainability of any potential gains.

How Does OLN's Valuation Compare to Its History? MetricCurrentHistorical P/E (TTM)Not Available10.0x Forward P/E188.8xN/A As the current P/E ratio is not available, we cannot compare it directly with the 5-year median P/E of 10.0x. However, the forward P/E of 188.8x indicates that the stock is priced significantly above historical valuation levels. This analysis aligns with the GF Value™ verdict, suggesting that while the stock is currently undervalued based on price, it may be overvalued when taking future earnings expectations into account.

What Does OLN's GF Score™ Tell Us? MetricRating GF Score™63/100 Financial Strength3/10 Profitability5/10 Growth3/10 Valuation4/10 Momentum9/10 The GF Score™ of 63/100 suggests that Olin Corp has potential for above-average performance, primarily driven by its momentum rank of 9/10. However, the financial strength score of 3/10 and growth rank of 3/10 indicate significant weaknesses that could affect long-term performance. The profitability and valuation ranks of 5/10 and 4/10, respectively, suggest that while the company has made some strides in profitability, there are still considerable concerns regarding its valuation metrics.

What Are Insiders Doing with OLN Stock? In the last three months, there have been no insider transactions reported for Olin Corp OLN . This lack of insider activity may suggest uncertainty about the company's future prospects, as typically, insider buying can indicate confidence in the company's performance. The absence of buying or selling signals may also indicate that insiders are taking a wait-and-see approach in light of recent stock performance.

What This Means for Investors Based on the GF Value™ analysis, Olin Corp OLN is currently undervalued, trading at $25.87 compared to an estimated fair value of $45.61. However, investors should approach with caution due to the potential value trap indicated by the GF Valuation label and the concerning financial strength metrics.

For the complete analysis, visit the Olin Corp OLN stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is OLN's GF Score™?

OLN has a GF Score™ of 63/100, suggesting that it has above-average potential for performance based on its key aspects.

Is OLN overvalued or undervalued?

OLN is currently undervalued, with a GF Value™ of $45.61 compared to its current price of $25.87, indicating a 43.3% margin of safety.

What is OLN's P/E ratio?

The current P/E ratio for OLN is not available, but the forward P/E is 188.8x, suggesting that the stock is trading at a premium compared to its historical valuation.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].